The presentations will center on the efficacy and safety profiles of several key investigational and established therapies. Among the highlights, Phase 3 results for retatrutide—a triple hormone receptor agonist—will demonstrate significant weight loss and A1C reductions in patients with type 2 diabetes. Additionally, data from the ACHIEVE-4 study will reinforce the cardiovascular safety of the oral medication Foundayo, also known as orforglipron.

Lilly is also slated to reveal Phase 2 data for eloraTZP, a triple-acting therapy combining eloralintide with tirzepatide. Beyond these new compounds, the company will share further insights from the SURPASS-CVOT trial, which evaluated the cardiovascular outcomes of Mounjaro in adults with established heart disease, and present exploratory proteomic findings from the SURMOUNT-5 study. These disclosures aim to provide a deeper biological understanding of how current and future treatments address the complexities of cardiometabolic disease.